Peptide CDMO Papiso: Boemo ba Maraka ba Bachem & Bohlokoa Bakhanni

Peptide CDMO Papiso ka Ha U habanya

Lipalo tsa karolo ea 'maraka li fapana ho ea ka tlhaloso ea 'maraka, 'me papiso ena ke ea lipatlisiso feela, ho hula litlaleho tsa sechaba le tlaleho ea khoebo ho e-na le tekanyetso e laetsoeng.

U Lokela ho Hlahloba Breadth ea Teknoloji Joang?

Bophara ba tekheniki ke bokhoni ba ho kopanya le ho tšoaea tatellano e thata, eseng palo ea li-amino acid tse boleloang ke bukana. Bolelele bo sebetsang ba maiketsetso bo lekanyelitsoe ho hoo e ka bang 50 ho 70 masalla hobane tatellano e khutsufalitsoeng le litšila lia bokellana ha ketane e ntse e hola.; ho feta moo, solid-phase synthesis le tharollo-phase fragment condensation li kopantsoe ho fihlela lipheo tse telele kapa tse thata. (Neuland Labs, 2025-07-31).

Moeli oo o bohlokoa hobane li-truncations tse tsoang ho coupling li bokellana ka bolelele ka bolelele, 'me litšila tse ke keng tsa hlokomolohuoa ka tekanyo ea milligram li fetoha lintho tse bonahalang ka tekanyo ea lik'hilograma tse ngata. Liforomo tse kopaneng le tse sa phuthoang hantle li tlameha ho bonoa, 'me tlhoekiso e tlameha ho ntlafatsoa hape bakeng sa sehlopha se seholoanyane (Neuland Labs, 2025-07-31). Ona ke mokhoa oa ho hloleha o arohanyang botebo ba 'nete ba botekgeniki ba morekisi ho tloha papatsong ea hae.

Marang-rang a phatlalalitsoeng a Bachem a fihla Bubendorf, Sisslerfeld, Vionnaz, Vista, Torrance le St. Helens, ka likarolo tsa bokhoni tse arotsoeng ka boomo ho ea ka sebaka. Phatlalatso ea eona ea halofo ea selemo e hlalosa Vista e le ho holisa bokhoni bo phahameng ha matsete a Western Switzerland a ikemiselitse ho fumana li-precursor tsa bohlokoa., ho bolelang hore tšebeliso e itseng ea chelete e reka tšireletso ea pele ho e-na le bokhoni ba API (Bachem, 2026-07-30).

Li-CDMO tsa litsebi li qothisana lehlokoa le maemo a fapaneng. Lethathamo la liphetoho tse hatisoang ke setsebi le akaretsa cyclic, e nang le disulfide e ngata, stapled, PEGylated, e nang le mafura, glycosylated le D- kapa tatellano eo eseng ya tlhaho-masala-e ruisang, ka mekhoa ea libaesekele ho kenyeletsoa hlooho-to-mohatla, ka ketane-to-hlakoreng le ketane le hydrocarbon stapling, mmoho le orthogonal Li-Peptide tsa Synthetic Setšoantšo sa analytics sa LC-UV, LC-MS/HRMS e nang le deconvolution ea bongata bo sa fetoheng, 'mapa oa peptide, litlhahlobo tsa karo-karolelano ea chiral le epimer, le NMR bakeng sa khokahanyo ea macrocycle kapa disulfide (Alpha CDMO, 2025-12-25).

Morekisi e moholo ea kopaneng hangata o hapa ka bophara ba sekala se ngolisitsoeng. Setsebi se ka hlola ka phetoho e le 'ngoe e makatsang. Ka hona bophara ke potso ea potefolio, eseng potso ea boholo, 'me ke ea haufi le holimo ho litekanyetso life kapa life tsa tlhahlobo ea mofani oa peptide.

Ke Mofani Efe ea Nang le Mekhoa e Matla ea Boleng?

Litsamaiso tsa boleng lia hlahlojoa, eseng takatso, kahoo papiso mona e pakeng tsa litlaleho ho e-na le botumo. Boemo ba ts'ebetso bo ntse bo eketseha: FDA e fane ka eona 303 lithethefatsi le biologics Litemoso Mangolo a FY2025 khahlanong le 190 ka FY2024, litlhahlobo tsa lisosa tsa lithethefatsi tsa batho le libaka tsa biologic li ile tsa sebetsa ka mokhoa o batlang o lekana 250% ka holimo ho motheo ka 2025, le boikarabello ba likarolo tsa taolo ea boleng e bile taba e qotsitsoeng holimo ea tlhahlobo bakeng sa selemo sa bohlano se latellanang. Tlaleho ea Directional e boetse e fana ka maikutlo a ho potoloha 30% ea Mangolo a Temoso ho meaho ea China API ho tloha 2024 e ne e na le liphuputso tsa botšepehi ba data, le hoja ho se denominator e hatisitsoeng ka palo eo.

Bongata ba mefokolo eo ke ea konteraka pele e ka ba tekheniki. Likheo tsa tumellano ea boleng tseo FDA e li qotsang morao ho 21 CFR 211.22(a) le (d): ha ho tumellano e hlophisitsoeng ea boleng, boikarabello bo abetsoeng "mahlakore ka bobeli" kahoo ha ho motho ea nang le lipatlisiso tsa ho kheloha kapa tokollo ea sehlopha, mesebetsi ea tlhahiso e setseng e sa baloa, taolo ya phetoho e sa hlalosoang, le litifikeiti tsa tlhahlobo ea mofani oa thepa li amoheloa ntle le netefatso. Batšehetsi ba koala sekheo seo ka ho batla li-CoA tse khethehileng tse sa fetotsoeng, bohloeki bo bongata le lintlha tse amanang le lintho tse amanang le tsona, tumellano ya boleng e akaretsang taolo ya phetoho, ho koaloa ha kheloha le litokelo tsa ho hlahloba, le boitsebiso ba sebaka sa sebele sa tlhahiso le mohala ho e-na le kakaretso ea khoebo.

Phatlalatso ea Bachem ka boeena ea hore mohaho oa ho haha ​​​​K o bitsa litšenyehelo tsa H1 2026 liphetho tsa ts'ebetso, e koahetsoe ka tlaleho ea khoebo ka lenaneo la ho atolosa Bachem, ke ponts'o ea ponaletso e lokelang ho lekanyetsoa. Sekala feela ha se supe letho: one published supplier scorecard flags utilisation above 85% with no expansion plan and CAPA backlogs beyond 90 matsatsi, meaning corrective and preventive action queues that stall, as risks that apply to any supplier regardless of size. The supplier that shows you its deviation and CAPA data wins, and that is a question you ask, not a claim you read.

Na E phatlalalitsoe ke Matla a Equal Qualified Capacity?

Announced reactor volume is not qualified capacity, and the gap between the two is where programs slip. An industry capacity tally puts global peptide API utilisation at 87–91% in 2026 against a sustainable long-run average of 70–75%, which means the constraint is real before any new build is counted (peptidestaff capacity-expansion analysis, kgutlisitsoe 2026-09-18). The same tally estimates 18–36 months for large-scale SPPS capacity, 14–22 months order-to-delivery for synthesis equipment, le likhoeli tse 18-24 ho tšoaneleha li-lyophilizers tsa boemo ba indasteri, ka bongata bo bocha bo fumanehang khoebong feela ka 2027-2029.

Phatlalatso ea Bachem ea halofo ea selemo e hlahisa phapang ka mokhoa o hloekileng: Building K e "kentsoe tšebetsong ka katleho ka 2026," lihlahisoa tsa khoebo tsa GMP li se li entsoe moo., mme setsi "se ntse se atolosoa butle-butle ho fana ka bokhoni bo eketsehileng" (Bachem ad-hoc tokollo, 2026-07-30). Ke bokhoni ba ho sebetsa, eseng khakanyo. Tlaleho ea khoebo ka lenaneo la ho atolosa Bachem e bonts'a capex ea marang-rang e qalang Bubendorf, Sisslerfeld, Vionnaz, Vista, Torrance le St. Helens, le Bubendorf e tsepamisitse maikutlo ho fokotsa mathata a itseng hammoho le leano la ts'ebetso la ho notlolla bokhoni ka ho ntlafatsa ts'ebeliso ea meaho e teng. (Pharma Manufacturing, 2026-07-31).

Phaephe e eang pele ke ea nako e telele. Phatlalatso ea Sisslerfeld e fana ka chelete e fetang CHF 500m mohatong oa pele ka tlhahiso e lebelletsoeng ke 2030 (Bachem ad-hoc tokollo, 2026-07-30), 'me tlaleho ea khoebo e beha matsete a ka bang teng ka holimo ho CHF 1.2bn le balekane ba eketsehileng (Pharma Manufacturing, 2026-07-31). Ho pholletsa le lefapha, e phatlalalitse matsete a matla a CDMO a peptide a fihlile hoo e ka bang $2.4bn selemo ho fihlela joale 2026 ho fihlela likhoeling tse hlano tsa pele, palo ea bokhoni ba indasteri ho fapana le palo e hlahlobiloeng (peptidestaff capacity-expansion analysis, kgutlisitsoe 2026-09-18).

Morekisi ea se nang moaho o mocha o ntse a ka hlola ho fumaneha ha nako e haufi haeba a ntlafalitse likhoele tse teng., kahoo ho phatlalatsoa chelete ke proxy e fokolang bakeng sa seo u ka se khonang. Botsa hore na ke eng e tšoanelehang kajeno, se tshwanelehang ka dikgwedi tse leshome le metso e mmedi, le hore na phatlalatso ea litaba ke eng.

U Lokela ho Lebella Ho Itloaetsa ho Hokae?

Ho itloaetsa ho bolela hore morekisi a ka fetola tsela, sekala, nehelano le analytics ntle le ho buisana bocha. Ka tshebetso, seo se arola lipotso tse peli tse fapaneng haholo, le ho tseba hore na ke efe eo u e botsang ke motheo oa litekanyetso tsa tlhahlobo ea mofani oa peptide.

Ea pele ke k'hemistri. Setsebi se tla hlalosa lihlopha tsa ho fetola le mekhoa ea ho palama baesekele eo e ka e sebelisang, le li-analytics tse li pakang: LC-UV, LC-MS/HRMS e nang le deconvolution ea bongata bo sa fetoheng, 'mapa oa peptide, litlhahlobo tsa karo-karolelano ea chiral le epimer, le NMR bakeng sa khokahanyo ea macrocycle kapa disulfide, joalo ka ha ho boletsoe lenaneng la ntlafatso le phatlalatsoang ke setsebi. Ea bobeli ke ts'ebetso. Mehato ea tlhoekiso e joalo ka HPLC e itokisang le chromatography e tsoelang pele e tlameha ho ntlafatsoa hape ka bongata., ke ka lebaka leo synthesis scale-up e hlōlehang ka lehlakoreng le ka tlaase ho noka hangata ho feta ho resin.

Phatlalatso ea Bachem ea halofo ea selemo e hlalosa mohlala o fapaneng oa sebaka sa marang-rang, kahoo ho itloaetsa ho na le karolo ea potso ea ho tsamaisa: saete efe, moleng ofe, phepelo ea selelekela. Ho e-na le hoo, litsebi li qothisana lehlokoa le moralo oa litsela o le mong oa tatellano e thata.

The nuance bohlokoa. Bakeng sa tatellano e tloaelehileng ea GLP-1, customization hangata ke ea khoebo, taba ea slots, linako le litokomane. Bakeng sa analogue ea stapled kapa lipidated, ke qeto eohle.

Kahlolo: bapisa potso ea ho iketsetsa motho le sehlopha sa hau sa molek'hule pele o bapisa barekisi ho hang.

Kamoo Mofani e Mong le e Mong a Arabelang Kateng?

Karabelo ke mokhoa o le mong oa tlhahlobo ea mofani oa peptide hoo e batlang e se le e 'ngoe ea rekoto ea sechaba e koahelang. E hlaha ka nako ea phetisetso ea theknoloji, linako tsa ho kheloha le phetoho ea taolo ea phetoho, mme dipalo tseo di phela ka ditumellano tsa boleng, eseng litlalehong tsa selemo kapa likhatisong tsa litaba. Seo e leng sechaba ke mokhoa oa ho hloleha: likheo tsa tumellano ea boleng li qotsoa ke FDA, moo phetoho ea taolo, Litokelo tsa ho koala leano la ho kheloha ha ho ka ha ngoloa fatše, ke likheo tse tšoanang tse ntseng li eketseha ho fihlela liphetho tsa tlhahlobo.

Ka sebopeho, morekisi e moholo ea kopantseng o fana ka mekhoa e mengata e ts'oanang empa ho na le li-handoffs tse ngata lipakeng tsa tsona; setsebi se khutsufatsa ketane ea liqeto empa se etsa mesebetsi e fokolang ka nako e le 'ngoe. Ka bobeli li senyeha ha li sebelisoa ka mokhoa o phahameng, le 2026 ke 'maraka o sebelisoang haholo, kahoo mehala ea litšupiso e nkuoeng kajeno e hlalosa mofani oa thepa tlas'a mojaro o fapaneng le oo u tla sebetsa le eena.

Hlokomela: Ha ho mohloli oa sechaba papisong ena o senolang linako tsa ho koala kapa tsa phetisetso ea theknoloji. Fumana lintlha tsena ho tsoa ho boiphihlelo ba hau ba tlhahlobo le phetisetso ea theknoloji, eseng ho tsoa litšupisong tsa morekisi.

Setšoantšo sa Theko se Bontša'ng?

Bakeng sa lenaneo le tloaelehileng la GMP peptide, theko hona joale e behiloe ke khaello ea bokhoni ho fapana le ka katleho ea bafani. Khatello ea litheko e tlalehiloeng ho GLP-1 peptide API e nyolositse litheko tsa tlhahiso ea likonteraka. 25 ho 40 liphesente ho tloha 2023, athe non-GLP-1 peptide API e ile ea phahama le ho feta 8 ho 15 peresente (tlhahlobo ea theko ea 'maraka, kgutlisitsoe 2026). Mohloli o tšoanang o beha mantsoe a qotsitsoeng a CDMO a China 30 ho 50 liperesente tse ka tlase ho barekisi ba Bophirimela bakeng sa mosebetsi o seng oa GLP-1 le ho 35 ho 50 liperesente tsa litheko tsa Bophirimela tsa GLP-1, leha e le khakanyo ea aggregator ntle le mokhoa o senotsoeng, le tse phetoang haholo 15 ho 25 percent band ha e hlahe leqepheng la mohloli.

Phatlalatso ea Bachem ea halofo ea selemo e bonts'a hore morekisi oa litšupiso a nka litšenyehelo tsa katoloso ho fapana le ho li fetisa ka mokhoa o hloekileng.: H1 2026 EBITDA margin e kene ka 25.4 peresente kgahlanong le 29.1 lekholong pele ho selemo (Tlaleho ea halofo ea selemo ea Bachem, 2026). Khatello eo e latela ea k'hamphani 2026 tataiso ea CHF 350 ho 400 limillione tsa tšebeliso ea chelete, CHF 148.4 milione ea eona e seng e tsetelitsoe ho H1 2026 (Bachem 2026 tataiso, 2026). Papiso ea CDMO ea peptide e hahiloeng ka theko ka gram ka hona e hloloheloa moo chelete e eang teng.

Theko e theko e tlaase e na le litšenyehelo tse phahameng ka ho fetisisa tsa ho tšoaneleha ha setša, line kapa sephutheloana sa data ha se hlake. Ho falla, ho tšoaneleha hape le li-analytics tsa tlatsetso li ka hlakola lekhalo la sehlooho ka botlalo.

Kahlolo: bapisa kakaretso ea litšenyehelo tsa thuto, eseng theko ka gram.

Ke Mang ea Lokelang ho Khetha Mofani ofe?

Haeba molek'hule ea hau ke tatellano e tloaelehileng maemong a khoebo, khetha mofani oa thepa ea nang le bokhoni bo tšoanelehang ba nako e haufi. Haeba molek'hule ea hau e le analogue e fetotsoeng kapa e thata ho e kopanya, khetha mofani oa thepa ea ka u bontšang tsela e ka bapisoang le litlhahlobo tsa eona. Molao oo oa karohano o le mong o jara boholo ba liqeto.

Biotech ea boemo ba bongaka e nang le peptide e fetotsoeng: beha pele pontšo ea litsela ho feta litšepiso tsa sekala. Kopa analogue e tšoanang, boemo ba eona bo sa hloekang, le li-analytics tse sebelisitsoeng ho e khetholla, hobane litlelase tsa phetoho tse thatafatsang motsoako ke hantle moo ts'ebetso e leng bohlokoa haholo (lethathamo la tlhahlobo ea phetoho eo setsebi se e phatlalatsang).

Batšehetsi ba maemo a khoebo ba hlokang phepelo ea boima ba lik'hilograma tse makholo: boima bo tšoanelehang ka holim'a liphatlalatso tsa sehlooho. Li-reactor tse phatlalalitsoeng le lotho tse lokollotsoeng ke lintho tse fapaneng, 'me lekhalo pakeng tsa tsona ke moo nako e thellang (Phatlalatso ea Bachem ea halofo ea selemo e bontša kamoo k'hamphani ka boeona e arolang likarolo tsa bokhoni ba sebaka sa marang-rang).

Ts'ehetso ea ho fapanyetsana hole le ho itšetleha ka sebaka se le seng: tšoara phetisetso ea theknoloji e le moeli oa litšenyehelo, eseng tloaelo. Ho tšoaneleha hape, phetiso ya mokgwa wa tshekatsheko, le lifaele tsa taolo kaofela li qala bocha ha sebaka se fetoha (ke hobane'ng ha synthesis scale-up e hlōleha ho ngola mekhoa ea ho hlōleha).

Sehlopha sa thuto kapa sa ho sibolla pele: ntlafatsa bakeng sa ho feto-fetoha ha litsela le phihlello ea li-batch tse nyane ho fapana le bokhoni ba khoebo.

Ha mofani e moholo ea kopantseng kapa setsebi ha a lekane, karabo hangata ke dual-sourcing: sebelisa lintlha tse ka holimo e le molao oa karohano, ho fana ka lenaneo le leng le le leng ho mofani oa thepa ea hlōlang boemo ba eona bo ka sehloohong. Ts'ebetso ea tlhahlobo e shebaneng le litokomane, joalo ka ha MOL Changes e hlalosa, e ka u thusa ho fumana lintlha tsa tlhahlobo ea mofani oa peptide ka mokhoa o ts'oanang ho batho bohle pele o itlama.

Haeba u lekanya barekisi ba babeli ba thathamisitsoeng, bapisa bokhoni ba bona khahlanong le lithibelo tsa lenaneo la hau pele ho qeto e latelang ea sehlopha.

Lipotso Tse Botsoang Khafetsa

Na Bachem ke CDMO ea peptide e ntle ka ho fetisisa?

Ha ho na mofani oa thepa a le mong ea molemo ka ho fetisisa ho latela mokhoa o mong le o mong, 'me karabo e tšepahalang e itšetlehile ka hore na ke efe ea litekanyetso tse hlano tsa tlhahlobo ea hau e boima haholo. Boemo ba 'maraka ba Bachem bo matla ka ho fetisisa ho litsamaiso tsa boleng le botebo ba litokomane tsa taolo, e bohlokoa haholo bakeng sa mananeo a morao-rao le a khoebo. Mofani oa thepa ea hloahloa e ka ba ea loketseng hamolemo ha tatelano ea hau e hloka k'hemistri e sa tloaelehang kapa ha o hloka karabelo lenaneong le lenyenyane.. Tšoara sena e le papiso ea CDMO ea peptide e tsamaisoang ke profil ea hau ea lenaneo, eseng boemo.

Na re ka fetola li-CDMO tsa peptide bohareng ba lenaneo?

Ee, but the cost sits in the transfer, not the decision. Moving a program means re-establishing the synthesis route at the new site, transferring and re-validating analytical methods, and re-qualifying the supplier’s processes against your specification. That work is the same reason why synthesis scale-up fails when a route is locked too early: the chemistry, eseng lipampiri, is usually what resists transfer. Budget the effort before you commit to the move.

Na re ka sebelisa li-CDMO tse peli tsa peptide ka nako e le 'ngoe?

Ee, and dual-sourcing is common, but the split matters. The usual pattern separates precursor supply from final API manufacture, which Bachem’s own half-year disclosure describes as part of how it manages capacity across sites. Splitting at the precursor stage keeps the regulated final step with one qualified supplier while adding a second source upstream. Ho arola mohato oa API ka boeona libakeng tse peli ho eketsa papiso ea hau le moroalo oa taolo ea phetoho.

Ke ntlha efe e bohlokoa haholo bakeng sa peptide e fetotsoeng?

Bophara ba tekheniki le mokhoa oa ho itloaetsa li na le boima bo boholo hang ha tatellano ea hau e siea k'hemistri e tloaelehileng. Masalla ao e seng a tlhaho, cyclization, conjugation le liphetoho tse sa tloaelehang ho fokotsa tšimo kapele, hobane ha se sethala se seng le se seng sa morekisi se sebetsanang le bona ka bongata. Sebetsa ka lethathamo la liphetoho tseo setsebi se li phatlalatsang khahlano le bokhoni bo boletsoeng ba mokhethoa e mong le e mong pele u lekanya theko kapa kemiso ea nako..

E phatlalalitsoe 2026 matla a fetola setšoantšo sa nako e haufi?

E seng haholo. Bokhoni ba CDMO e ncha ea peptide ke boholo ba 2027 ho 2030 pale: phatlalatso ea Sisslerfeld e beha tlhahiso e eketsehileng qetellong ea fensetere eo, le palo ea bokhoni ba indasteri e bonts'a boholo ba sebaka se secha sa ho lulisa 2027 ho 2029. Bakeng sa mananeo a hlokang bokhoni bo tšoanelehang likhoeling tse leshome le metso e 'meli ho isa ho tse leshome le metso e robeli tse tlang, khaello ke boemo ba ts'ebetso, e seng ho panya ha nakoana.

Kahlolo: Moo Mofuta o Mong le o Mong oa Mofani o Hlōlang

Molao oa qeto ho tloha ha ho buloa o tšoara ka mor'a tlhahlobo: khetha e moholo mosebetsing ha lenaneo la hau le hloka rekoto e tebileng ea taolo le bokhoni bo boholo bo tšoanelehang, 'me u khethe setsebi ha tatellano ea hau e batla tsela e sa tloaelehang kapa kemiso ea hau ea nako e hloka mohala o tobileng ho batho ba etsang mosebetsi.. Ntho e lokelang ho rehoa mabitso ke hore tsena ha se maemo a sa feleng. Setsebi se eketsang sebaka sa bobeli sa marang-rang le nalane e khelohileng e qala ho hapa likarolo tseo e li lahleheloang hajoale, 'me motho ea ikarabellang ea hlophisang bocha ho potoloha sethala seo a seng a ntse a e-na le sona a ka koala lekhalo la ho itlhophisa ka potlako ho feta kamoo boholo ba eona bo bolelang..

E 'ngoe e phatlalalitsoeng ho fana ka lintlha tsa boima ba karete ea lintlha ho lumellana ha boleng ho 30 ho 40 peresente le bokgoni ponaletso ka 20 ho 30 peresente, ka botebo ba tekheniki le liphetho tsa bareki tse tlatsang karolo e setseng, e leng khopotso e molemo ea hore ha ho sehlopha se le seng se etsang qeto ea sephetho (one published supplier scorecard). Bala tafole joalo ka boemo ba ho qala, eseng letlapa la lintlha.

Mohato o latelang: Bapisa bokhoni khahlanong le tatellano ea hau le sethala. Haeba u batla maikutlo a bobeli hore na ke litekanyo life tse hlileng li leng boima bakeng sa lenaneo la hau, buisana le setsebi sa tekheniki pele u romela kopo e latelang ea tlhahiso.

Tsebiso: papiso ena e hatisitsoe ke MOL Changes, CDMO ea peptide. Lipalo tsa karohano ea 'maraka tse boletsoeng sengolong sena li fapana ho ea ka litlhaloso tsa mmaraka mme li lokela ho baloa joalo ka mekhahlelo ho fapana le maemo a tsitsitseng..